Design and Synthesis of O-Dialkylaminoalkyl Substituted Urolithin Derivatives: DNA Topoisomerase IIα Inhibition With Promising Antiproliferative Activity

IF 3.6 3区 医学 Q2 CHEMISTRY, MEDICINAL
Xintong Li, Xiaochun Zhang, Chan Yin, Chunhua Lu, Yuemao Shen
{"title":"Design and Synthesis of O-Dialkylaminoalkyl Substituted Urolithin Derivatives: DNA Topoisomerase IIα Inhibition With Promising Antiproliferative Activity","authors":"Xintong Li,&nbsp;Xiaochun Zhang,&nbsp;Chan Yin,&nbsp;Chunhua Lu,&nbsp;Yuemao Shen","doi":"10.1002/ardp.70009","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>Based on the pharmacophore structural characteristics of topoisomerase II (TopoII) inhibitors: (i) planar polyaromatic skeleton; (ii) the cation core; (iii) a groove-binding side chain moiety, 16 urolithin derivatives with <i>O</i>-dialkylaminoalkyl substitutions were designed and synthesized. Most of the synthesized compounds showed improved TopoIIα inhibitory and antiproliferative activities. <b>20</b> with the best TopoIIα inhibitory activity also exhibited excellent antiproliferative activity with IC<sub>50</sub> values of 0.91 ± 0.01, 1.93 ± 0.04, and 2.84 ± 0.34 μM against the MDA-MB-231, HeLa, and A549 cell lines, being about 12.55, 3.95, and 2.17 times more active than VP-16 (IC<sub>50</sub> 11.42 ± 0.82, 7.63 ± 0.46, and 6.15 ± 0.43 μM, respectively). Meanwhile, <b>20</b> exhibited weak toxicity to normal cells. In addition, <b>20</b> exerted anti-migration and anti-invasion activity against MDA-MB-231 cells. Our results supported that <b>20</b> might act as TopoIIα inhibitor with the potential to become a new type of antitumor drug lead.</p></div>","PeriodicalId":128,"journal":{"name":"Archiv der Pharmazie","volume":"358 5","pages":""},"PeriodicalIF":3.6000,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archiv der Pharmazie","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/ardp.70009","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

Based on the pharmacophore structural characteristics of topoisomerase II (TopoII) inhibitors: (i) planar polyaromatic skeleton; (ii) the cation core; (iii) a groove-binding side chain moiety, 16 urolithin derivatives with O-dialkylaminoalkyl substitutions were designed and synthesized. Most of the synthesized compounds showed improved TopoIIα inhibitory and antiproliferative activities. 20 with the best TopoIIα inhibitory activity also exhibited excellent antiproliferative activity with IC50 values of 0.91 ± 0.01, 1.93 ± 0.04, and 2.84 ± 0.34 μM against the MDA-MB-231, HeLa, and A549 cell lines, being about 12.55, 3.95, and 2.17 times more active than VP-16 (IC50 11.42 ± 0.82, 7.63 ± 0.46, and 6.15 ± 0.43 μM, respectively). Meanwhile, 20 exhibited weak toxicity to normal cells. In addition, 20 exerted anti-migration and anti-invasion activity against MDA-MB-231 cells. Our results supported that 20 might act as TopoIIα inhibitor with the potential to become a new type of antitumor drug lead.

Abstract Image

邻二烷基氨基取代尿素衍生物的设计与合成:DNA拓扑异构酶ⅱα抑制与有希望的抗增殖活性
基于拓扑异构酶II (TopoII)抑制剂药效团结构特征:(i)平面多芳骨架;(ii)阳离子核;(iii)设计并合成了16个以o -二烷基氨基取代的尿素衍生物。大多数合成的化合物具有较好的TopoIIα抑制和抗增殖活性。TopoIIα抑制活性最高的20对MDA-MB-231、HeLa和A549细胞株的IC50分别为0.91±0.01、1.93±0.04和2.84±0.34 μM,分别是VP-16的12.55、3.95和2.17倍(IC50分别为11.42±0.82、7.63±0.46和6.15±0.43 μM)。其中20种对正常细胞呈弱毒性。其中20种对MDA-MB-231细胞具有抗迁移和抗侵袭活性。我们的研究结果支持20可能作为TopoIIα抑制剂,具有成为新型抗肿瘤药物lead的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Archiv der Pharmazie
Archiv der Pharmazie 医学-化学综合
CiteScore
7.90
自引率
5.90%
发文量
176
审稿时长
3.0 months
期刊介绍: Archiv der Pharmazie - Chemistry in Life Sciences is an international journal devoted to research and development in all fields of pharmaceutical and medicinal chemistry. Emphasis is put on papers combining synthetic organic chemistry, structural biology, molecular modelling, bioorganic chemistry, natural products chemistry, biochemistry or analytical methods with pharmaceutical or medicinal aspects such as biological activity. The focus of this journal is put on original research papers, but other scientifically valuable contributions (e.g. reviews, minireviews, highlights, symposia contributions, discussions, and essays) are also welcome.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信